Payment overview · 2025
General Payments
$408.15
14 reported records · 10 companies
Healthcare provider profile · identity verified
Morris Kliger, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LANSDALE, PA · NPI 1124080817
Verified facts
What the public records show
CMS Open Payments records show Morris Kliger, D.O. received $408.15 in general payments during 2025 across 14 reported records.
Janssen Biotech, Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $115.00 | 28.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $82.57 | 20.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.64 | 10.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.83 | 8.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.28 | 6.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.04 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.13 | 6.4% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $18.62 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.03 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.01 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $408.15 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $115.00 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $115.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $82.57 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.13 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 616 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 140 |
| Lisinopril | Lisinopril | 486 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 120 |
| Metformin Hcl | Metformin Hcl | 374 | 107 |
| Losartan Potassium | Losartan Potassium | 334 | 90 |
| Lorazepam | Lorazepam | 258 | 78 |
| Simvastatin | Simvastatin | 245 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 55 |
| Gabapentin | Gabapentin | 178 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 51 |
| Omeprazole | Omeprazole | 157 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 144 | 37 |
| Glimepiride | Glimepiride | 143 | 42 |
| Atenolol | Atenolol | 129 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 129 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 33 |
| Alprazolam | Alprazolam | 102 | 26 |
| Ozempic | Semaglutide | 94 | 17 |
| Methylprednisolone | Methylprednisolone | 86 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 30 |
| Tramadol Hcl | Tramadol Hcl | 80 | 18 |
| Allopurinol | Allopurinol | 73 | 23 |
| Januvia | Sitagliptin Phosphate | 73 | 13 |
| Sertraline Hcl | Sertraline Hcl | 73 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 20 |
| Glipizide | Glipizide | 68 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 22 |
| Trazodone Hcl | Trazodone Hcl | 64 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 17 |
| Famotidine | Famotidine | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Meloxicam | Meloxicam | 59 | 20 |
| Synthroid | Levothyroxine Sodium | 58 | 17 |
| Bupropion Xl | Bupropion Hcl | 57 | 13 |
| Eliquis | Apixaban | 57 | 17 |
| Clonazepam | Clonazepam | 54 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | 15 |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 16 |
| Montelukast Sodium | Montelukast Sodium | 50 | 12 |
| Diazepam | Diazepam | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 12 |
| Enalapril Maleate | Enalapril Maleate | 41 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 16 |
| Furosemide | Furosemide | 39 | 12 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 35 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Valsartan | Valsartan | 38 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 24 |
| Temazepam | Temazepam | 30 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Carvedilol | Carvedilol | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Prednisone | Prednisone | 21 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 14 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Colchicine | Colchicine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $408.15 · 14 records | Janssen Biotech, Inc. | ABRYSVO, AREXVY, CHARTIS CATHETER, COMIRNATY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, OTEZLA, Ohtuvayre, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, REPATHA, SHINGRIX, SIMPONI ARIA, TREMFYA, VOQUEZNA, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error